Caribou Biosciences Inc
General ticker "CRBU" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $182.8M
Caribou Biosciences Inc does not follow the US Stock Market performance with the rate: -27.8%.
Estimated limits based on current volatility of 2.7%: low 1.76$, high 1.85$
Factors to consider:
- US accounted for 96.0% of revenue in the fiscal year ended 2022-12-31
- Current price 55.1% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [3.99$, 8.74$]
- 2024-12-30 to 2025-12-30 estimated range: [4.23$, 9.07$]
Financial Metrics affecting the CRBU estimates:
- Negative: Non-GAAP EPS, $ of -1.45 <= 0.10
- Negative: Operating profit margin, % of -77.10 <= 1.03
- Negative: Operating cash flow per share per price, % of -17.59 <= 2.35
- Negative: negative Net income
- Positive: -0.96 < Investing cash flow per share, $ of -0.92
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Positive: Interest expense per share, $ of 0 <= 0
Short-term CRBU quotes
Long-term CRBU plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $9.60MM | $13.85MM | $34.48MM |
| Operating Expenses | $76.58MM | $120.25MM | $150.54MM |
| Operating Income | $-66.98MM | $-106.40MM | $-116.06MM |
| Non-Operating Income | $0.38MM | $7.05MM | $14.18MM |
| Interest Expense | $0.01MM | $0.00MM | $0.00MM |
| R&D Expense | $52.26MM | $82.23MM | $112.08MM |
| Income(Loss) | $-66.60MM | $-99.35MM | $-101.88MM |
| Taxes | $0.32MM | $0.07MM | $0.19MM |
| Profit(Loss) | $-66.92MM | $-99.42MM | $-102.07MM |
| Stockholders Equity | $387.82MM | $300.87MM | $368.40MM |
| Inventory | $31.11MM | $62.57MM | $0.00MM |
| Assets | $442.36MM | $373.76MM | $432.21MM |
| Operating Cash Flow | $-32.52MM | $-90.97MM | $-93.29MM |
| Capital expenditure | $3.12MM | $7.05MM | $11.61MM |
| Investing Cash Flow | $-176.40MM | $-93.25MM | $-68.18MM |
| Financing Cash Flow | $433.43MM | $2.13MM | $154.30MM |
| Earnings Per Share* | $-1.11 | $-1.64 | $-1.38 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.